These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 8638026)
41. Controlling cardiac arrhythmias: an overview with a historical perspective. Singh BN Am J Cardiol; 1997 Oct; 80(8A):4G-15G. PubMed ID: 9354407 [TBL] [Abstract][Full Text] [Related]
42. Long-term reproducibility of electrophysiologically guided therapy with sotalol in patients with ventricular tachyarrhythmias. Mewis C; Kühlkamp V; Mermi J; Bosch RF; Seipel L J Am Coll Cardiol; 1999 Jun; 33(7):1989-95. PubMed ID: 10362204 [TBL] [Abstract][Full Text] [Related]
43. A comparison of long-standing implantable cardioverter-defibrillator patients with and without appropriate therapy for ventricular arrhythmias: impact of a widening QRS. Dizon J; Chen K; Dizon S; Biviano A; Whang W; Ehlert F; Vazquez J; Nazif T; Garan H Europace; 2011 Jan; 13(1):77-81. PubMed ID: 21149513 [TBL] [Abstract][Full Text] [Related]
44. Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent. Singh BN Am J Cardiol; 1996 Aug; 78(4A):41-53. PubMed ID: 8780328 [TBL] [Abstract][Full Text] [Related]
45. [Effect of drug therapy on frequency of adequate discharges of implanted cardioverter defibrillator]. Tiroke A; Ganeeva ON Kardiologiia; 2003; 43(6):54-8. PubMed ID: 12891312 [TBL] [Abstract][Full Text] [Related]
46. Choice and chance in drug therapy of cardiac arrhythmias: technique versus drug-specific responses in evaluation of efficacy. Singh BN Am J Cardiol; 1993 Nov; 72(16):114F-124F. PubMed ID: 8237824 [TBL] [Abstract][Full Text] [Related]
47. Effect of Baseline Antiarrhythmic Drug on Outcomes With Ablation in Ischemic Ventricular Tachycardia: A VANISH Substudy (Ventricular Tachycardia Ablation Versus Escalated Antiarrhythmic Drug Therapy in Ischemic Heart Disease). Parkash R; Nault I; Rivard L; Gula L; Essebag V; Nery P; Tung S; Raymond JM; Sterns L; Doucette S; Wells G; Tang ASL; Stevenson WG; Sapp JL Circ Arrhythm Electrophysiol; 2018 Jan; 11(1):e005663. PubMed ID: 29305400 [TBL] [Abstract][Full Text] [Related]
48. Influence of Holter monitor and electrophysiologic study methods and efficacy criteria on the outcome of patients with ventricular tachycardia and ventricular fibrillation in the ESVEM trial. Reiffel JA; Reiter MJ; Freedman RA; Mann D; Huang SK; Hahn E; Hartz V; Mason J; Prog Cardiovasc Dis; 1996; 38(5):359-70. PubMed ID: 8604440 [TBL] [Abstract][Full Text] [Related]
49. Cost and efficacy analysis in the ESVEM trial: implications for diagnosis and therapy for ventricular tachyarrhythmias. Hlatky MA Prog Cardiovasc Dis; 1996; 38(5):371-6. PubMed ID: 8604441 [TBL] [Abstract][Full Text] [Related]
50. Clinical usefulness of electrophysiologic testing in patients with ventricular tachycardia and chronic chagasic cardiomyopathy treated with amiodarone or sotalol. Leite LR; Fenelon G; Simoes A; Silva GG; Friedman PA; de Paola AA J Cardiovasc Electrophysiol; 2003 Jun; 14(6):567-73. PubMed ID: 12875414 [TBL] [Abstract][Full Text] [Related]
51. Proarrhythmias and antiarrhythmias: two sides of the same coin. Kowey PR; Yan GX Heart Rhythm; 2005 Sep; 2(9):957-9. PubMed ID: 16171750 [No Abstract] [Full Text] [Related]
52. [Ventricular cardiac arrhythmias. New anti-arrhythmia agents]. Scholz H Z Kardiol; 1996; 85 Suppl 6():91-6. PubMed ID: 9064988 [TBL] [Abstract][Full Text] [Related]
53. A multicentre, double-blind randomized crossover comparative study on the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease. Boriani G; Lubinski A; Capucci A; Niederle R; Kornacewicz-Jack Z; Wnuk-Wojnar AM; Borggrefe M; Brachmann J; Biffi M; Butrous GS; Eur Heart J; 2001 Dec; 22(23):2180-91. PubMed ID: 11913480 [TBL] [Abstract][Full Text] [Related]
54. Lessons from antiarrhythmic trials involving class III antiarrhythmic drugs. Yap YG; Camm AJ Am J Cardiol; 1999 Nov; 84(9A):83R-89R. PubMed ID: 10568665 [TBL] [Abstract][Full Text] [Related]
55. [Implantable cardioverter defibrillator does not eliminate need for antiarrhythmic drugs in secondary prevention of life threatening ventricular arrhythmias. Results of OPTIC trial]. Iavelov IS Kardiologiia; 2006; 46(3):74-5. PubMed ID: 16710262 [No Abstract] [Full Text] [Related]
56. The ESVEM trial: impact on treatment of ventricular tachyarrhythmias. Electrophysiologic Study Versus Electrocardiographic Monitoring. Reiter MJ Pacing Clin Electrophysiol; 1997 Feb; 20(2 Pt 2):468-77. PubMed ID: 9058850 [TBL] [Abstract][Full Text] [Related]
57. Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, D,L-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs. Finance O; Manning A; Chatelain P J Cardiovasc Pharmacol; 1995 Oct; 26(4):570-6. PubMed ID: 8569217 [TBL] [Abstract][Full Text] [Related]
58. Class III antiarrhythmic agents: the next wave. Bauman JL Pharmacotherapy; 1997; 17(2 Pt 2):76S-83S; discussion 89S-91S. PubMed ID: 9085343 [TBL] [Abstract][Full Text] [Related]
59. Long-term cost-effectiveness of alternative management strategies for patients with life-threatening ventricular arrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring (ESVEM) Investigators. Hlatky MA; Boothroyd DB; Johnstone IM; Marcus FI; Hahn E; Hartz V; Mason JW J Clin Epidemiol; 1997 Feb; 50(2):185-93. PubMed ID: 9120512 [TBL] [Abstract][Full Text] [Related]